International Clinical Trial: A single-arm, open-label, phase II clinical study of iparomlimab and tuvonralima combined with chemotherapy and bevacizumab followed by sequential radiotherapy for unresectable or metastatic melanoma

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120280) titled 'A single-arm, open-label, phase II clinical study of iparomlimab and tuvonralima combined with chemotherapy and bevacizumab followed by sequential radiotherapy for unresectable or metastatic melanoma' on March 11.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The affiliated hospital of southwest medical university

Condition: Patients with unresectable or metastatic stage III or IV acral melanoma

Intervention: Trial Group:Epatolitorovarelimab 5mg/kg Q3W + Carboplatin AUC 5 or Cisplatin 75mg/m2 Q3W + Bevacizumab 5mg/kg D1 Q3W, one treatment cycle every 21 days for 4 cycles

Recr...